Clinical experience of cyclosporin treatment in patients with psoriasis and psoriatic arthritis

Oh, Eui Hyun; Koh, Won Seon; Shin, Jae Min; Kim, Jeong Eun; Ko, Joo Yeon; Ro, Young Suck

doi:10.1111/1346-8138.13746

Cited by 6 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The topical application of steroids and vitamin D3 analogues inhibits psoriatic inflammation and normalizes epidermal differentiation [38,39]. Systemic treatments, such as methotrexate, cyclosporine, phototherapy, and the phosphodiesterase 4 inhibitor apremilast, are useful for patients with extensive lesions [40][41][42][43][44][45].…”

Section: Introductionmentioning

confidence: 99%

Interleukin-17A and Keratinocytes in Psoriasis

Furue

Tsuji

et al. 2020

IJMS

176

155

View full text Add to dashboard Cite

The excellent clinical efficacy of anti-interleukin 17A (IL-17A) biologics on psoriasis indicates a crucial pathogenic role of IL-17A in this autoinflammatory skin disease. IL-17A accelerates the proliferation of epidermal keratinocytes. Keratinocytes produce a myriad of antimicrobial peptides and chemokines, such as CXCL1, CXCL2, CXCL8, and CCL20. Antimicrobial peptides enhance skin inflammation. IL-17A is capable of upregulating the production of these chemokines and antimicrobial peptides in keratinocytes. CXCL1, CXCL2, and CXCL8 recruit neutrophils and CCL20 chemoattracts IL-17A-producing CCR6+ immune cells, which further contributes to forming an IL-17A-rich milieu. This feed-forward pathogenic process results in characteristic histopathological features, such as epidermal hyperproliferation, intraepidermal neutrophilic microabscess, and dermal CCR6+ cell infiltration. In this review, we focus on IL-17A and keratinocyte interaction regarding psoriasis pathogenesis.

show abstract

Section: Introductionmentioning

confidence: 99%

Interleukin-17A and Keratinocytes in Psoriasis

Furue

Tsuji

et al. 2020

IJMS

176

155

View full text Add to dashboard Cite

show abstract

“…In addition, the CCL20/CCR6 chemotactic system is critically involved in the maintenance of the TNF‐α/IL‐23/IL‐17A axis. Therapeutic agents for psoriasis include topical steroids, topical vitamin D3 derivatives, phototherapy, phosphodiesterase‐4 inhibitors, cyclosporine, methotrexate and biologics targeting TNF‐α, IL‐23 and IL‐17A . As the TNF‐α/IL‐23/IL‐17A axis plays a pivotal role in the pathogenesis of psoriasis, the efficacy of anti–TNF‐α/IL‐23/IL‐17A biologics is excellent …”

Section: Introductionmentioning

confidence: 99%

“…Therapeutic agents for psoriasis include topical steroids, topical vitamin D3 derivatives, phototherapy, phosphodiesterase-4 inhibitors, cyclosporine, methotrexate and biologics targeting TNF-α, IL-23 and IL-17A. [38][39][40][41][42][43][44][45][46] As the TNF-α/IL-23/IL-17A axis plays a pivotal role in the pathogenesis of psoriasis, the efficacy of anti-TNF-α/IL-23/IL-17A biologics is excellent. 3,24,46 In this review, we will summarize the current research topics regarding the CCL20/CCR6 axis in psoriasis.…”

Section: Introductionmentioning

confidence: 99%

The CCL20 and CCR6 axis in psoriasis

et al. 2019

View full text Add to dashboard Cite

Psoriasis is a TNF‐α/IL‐23/IL‐17A–mediated inflammatory skin disease that causes a significant socioeconomic burden in afflicted patients. IL‐17A–producing immune cells, including Th17 cells, are crucial effector cells in the development of psoriasis. IL‐17A stimulates epidermal keratinocytes to produce CCL20, which eventually recruits CCR6 + Th17 cells into the lesional skin. Thus, the CCL20/CCR6 axis works as a driving force that prepares an IL‐17A–rich cutaneous milieu. In this review, we summarize the current research topics on the CCL20/CCR6 axis and the therapeutic intervention of this axis for psoriasis.

show abstract

“…Nonetheless, some studies support beneficial effects of cyclosporine on the symptoms of PSA in patients with skin psoriasis. 12,13 We do not recommend using the conventional drugs acitretin and fumarates in psoriasis patients with PSA as they are not indicated for the treatment of PSA. One study showed improvement of PSA with fumarates although confirmatory data are missing.…”

Section: Clinical Recommendationsmentioning

confidence: 99%

Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)

Lambert

Segaert²,

Ghislain

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Psoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis but also on co‐occurring diseases. In case of other coexisting inflammatory diseases, the right psoriasis treatment may improve both disorders. For infectious and malignant disorders, some treatments have to be avoided as they may be harmful. Objective The primary objective of this project was to collect evidence for the creation of practice guidelines for systemic treatment of psoriasis (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis). Methods Evidence‐based recommendations were formulated using a quasi‐Delphi methodology after a systematic search of the literature and a consensus procedure involving eight psoriasis experts. Results Recommendations are given on the use of systemic treatment in psoriatic arthritis, inflammatory bowel disease, demyelinating disorders, hepatitis B and C, HIV and cancer. Conclusion This expert opinion is a practical guide for dermatologists when handling psoriasis patients with these specific conditions.

show abstract

Clinical experience of cyclosporin treatment in patients with psoriasis and psoriatic arthritis

Cited by 6 publications

References 3 publications

Interleukin-17A and Keratinocytes in Psoriasis

Interleukin-17A and Keratinocytes in Psoriasis

The CCL20 and CCR6 axis in psoriasis

Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)

Contact Info

Product

Resources

About